{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010498","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.865929+00:00","generated_at":"2026-05-16T10:59:51.733029+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Delcath prelim FY2025 revenue $85.2M, HEPZATO $78.8M, cash $91M","bullets":["Total Q4 revenue ~$20.7M, FY revenue ~$85.2M; HEPZATO KIT Q4 ~$19.0M, FY ~$78.8M.","CHEMOSAT Q4 revenue ~$1.7M, FY ~$6.4M.","Cash and short-term investments ~$91.0M as of Dec 31, 2025; no debt.","628,572 shares repurchased for $6.0M under $25M buyback program.","25 active sites; ~140% growth in HEPZATO procedure volume YoY; positive operating cash flow in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010498","json":"https://secwatch.observer/filing/0001193125-26-010498.json","markdown":"https://secwatch.observer/filing/0001193125-26-010498.md","text":"https://secwatch.observer/filing/0001193125-26-010498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000119312526010498/0001193125-26-010498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000119312526010498/d52022d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:51.733029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}